AU2019328299B2 - PDE9 inhibitors for treating sickle cell disease - Google Patents

PDE9 inhibitors for treating sickle cell disease Download PDF

Info

Publication number
AU2019328299B2
AU2019328299B2 AU2019328299A AU2019328299A AU2019328299B2 AU 2019328299 B2 AU2019328299 B2 AU 2019328299B2 AU 2019328299 A AU2019328299 A AU 2019328299A AU 2019328299 A AU2019328299 A AU 2019328299A AU 2019328299 B2 AU2019328299 B2 AU 2019328299B2
Authority
AU
Australia
Prior art keywords
compound
weight
tablet
tablet composition
oral tablet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019328299A
Other languages
English (en)
Other versions
AU2019328299A1 (en
Inventor
Edward George CALAMAI
Michael Paul Dehart
Deborah Lynn Leithead DOBBINS
Shi Yin Foo
James Mcarthur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardurion Pharmaceuticals Inc
Original Assignee
Cardurion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardurion Pharmaceuticals Inc filed Critical Cardurion Pharmaceuticals Inc
Publication of AU2019328299A1 publication Critical patent/AU2019328299A1/en
Assigned to CARDURION PHARMACEUTICALS, INC. reassignment CARDURION PHARMACEUTICALS, INC. Request for Assignment Assignors: Imara Inc.
Application granted granted Critical
Publication of AU2019328299B2 publication Critical patent/AU2019328299B2/en
Priority to AU2025203611A priority Critical patent/AU2025203611A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019328299A 2018-08-31 2019-08-29 PDE9 inhibitors for treating sickle cell disease Active AU2019328299B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025203611A AU2025203611A1 (en) 2018-08-31 2025-05-19 PDE9 inhibitors for treating sickle cell disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862725725P 2018-08-31 2018-08-31
US62/725,725 2018-08-31
PCT/US2019/048898 WO2020047311A1 (en) 2018-08-31 2019-08-29 Pde9 inhibitors for treating sickle cell disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025203611A Division AU2025203611A1 (en) 2018-08-31 2025-05-19 PDE9 inhibitors for treating sickle cell disease

Publications (2)

Publication Number Publication Date
AU2019328299A1 AU2019328299A1 (en) 2021-04-22
AU2019328299B2 true AU2019328299B2 (en) 2025-02-20

Family

ID=69643759

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019328299A Active AU2019328299B2 (en) 2018-08-31 2019-08-29 PDE9 inhibitors for treating sickle cell disease
AU2025203611A Pending AU2025203611A1 (en) 2018-08-31 2025-05-19 PDE9 inhibitors for treating sickle cell disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025203611A Pending AU2025203611A1 (en) 2018-08-31 2025-05-19 PDE9 inhibitors for treating sickle cell disease

Country Status (10)

Country Link
US (2) US12213975B2 (enExample)
EP (1) EP3843737A4 (enExample)
JP (2) JP7579239B2 (enExample)
KR (2) KR20250108770A (enExample)
CN (2) CN119679736A (enExample)
AU (2) AU2019328299B2 (enExample)
CA (1) CA3110680A1 (enExample)
IL (1) IL281032A (enExample)
MA (1) MA53501A (enExample)
WO (1) WO2020047311A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
BR112020024019A2 (pt) 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
CN114072151A (zh) * 2019-05-07 2022-02-18 伊马拉公司 用于治疗地中海贫血的pde9抑制剂
US20230141118A1 (en) * 2020-04-13 2023-05-11 Bausch Health Ireland Limited Methods of using solid dispersions of rifaximin for the treatment of sickle cell disease
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2022036111A1 (en) * 2020-08-13 2022-02-17 Imara Inc. Methods and compositions for treating sickle cell disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018009424A1 (en) * 2016-07-06 2018-01-11 Imara, Inc. Pde9 inhibitors for treatment of peripheral diseases

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB587992A (en) 1944-12-11 1947-05-12 Charles William Scaife Improvements in and relating to the production of organic nitrogen compounds
US3578687A (en) 1968-01-30 1971-05-11 Texaco Inc Process for producing 4-nitroalkanoic acids
US3819561A (en) 1970-10-23 1974-06-25 Aerojet General Co Wetting agents for non-aqueous dispersions
JPS5313608B2 (enExample) 1972-06-16 1978-05-11
JPS5318013B2 (enExample) 1973-03-19 1978-06-13
US4599430A (en) 1981-12-21 1986-07-08 The Standard Oil Company Nitrogenation of hydrocarbons, including the production of maleimide
JPS62132804A (ja) 1985-12-05 1987-06-16 Aguro Kanesho Kk 植物生長調節剤
US5412137A (en) 1993-06-07 1995-05-02 Sandoz Ltd. Process for preparing phosphinyloxy propanaminium inner salt derivatives
AU2989695A (en) 1994-08-08 2000-03-07 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation
CN1088058C (zh) 1994-10-13 2002-07-24 肽技术有限公司 经修饰的多不饱和脂肪酸
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5741211A (en) 1995-10-26 1998-04-21 Medtronic, Inc. System and method for continuous monitoring of diabetes-related blood constituents
GB9618420D0 (en) 1996-09-04 1996-10-16 Scotia Holdings Plc Fatty acid treatment
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
JP4309045B2 (ja) 1997-10-30 2009-08-05 森下仁丹株式会社 不飽和脂肪酸またはその誘導体を内容物とするカプセル製剤およびその製造法
HU227841B1 (en) 1997-11-12 2012-05-02 Bayer Pharma AG 2-phenyl substituted imidazotriazinones, process for their preparation and pharmaceutical compositions thereof
US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6262029B1 (en) 1998-08-14 2001-07-17 Galenica Pharmaceuticals, Inc. Chemically modified saponins and the use thereof as adjuvants
KR20010101603A (ko) 1999-01-20 2001-11-14 노왈드 이미다조[1,5-ａ]-피리도[3,2-ｅ]-피라지논의 약제로서의용도
US6459003B1 (en) 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
AU5319499A (en) 1999-07-22 2001-02-13 Ivan L. Cameron Fatty acids to minimize cancer therapy side effects
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AUPQ291499A0 (en) 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
US6346231B1 (en) 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
IL139455A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20010037598A1 (en) 1999-12-14 2001-11-08 Suppes Galen J. Process for producing cetane improvers from triglycerides
IL151299A0 (en) 2000-02-16 2003-04-10 Brigham & Womens Hospital Aspirin-triggered lipid mediators
AR030416A1 (es) 2000-04-13 2003-08-20 Pharmacia Corp COMPUESTO DERIVADO HALOGENADO DEL ACIDO 2-AMINO-3,4 HEPTENOICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE Y SU USO EN LA FABRICACION DE UN MEDICAMENTO uTIL COMO INHIBIDOR DE LA OXIDO NITRICO SINTETASA
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
CN1232480C (zh) 2000-06-28 2005-12-21 萨宝集团公司 制备硝基烯烃的方法
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
EP1368022B1 (fr) 2001-03-02 2007-06-20 Debiopharm S.A. Utilisation d'un flacon contenant une solution d'oxaliplatine
DK1900364T3 (da) 2001-04-18 2014-01-13 Prometic Biosciences Inc Fedtsyrer, glycerider og analoger med medium kædelængde som neutrofile overlevelses- og aktiveringsfaktorer
US7105556B2 (en) 2001-05-30 2006-09-12 Bristol-Myers Squibb Company Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method
US20040176451A1 (en) 2001-06-18 2004-09-09 Tadakazu Tamai Pparg agonistic medicinal compositions
JP2005501096A (ja) 2001-08-17 2005-01-13 ユニヴァーシティ オブ ピッツバーグ 肥満、代謝症候群、糖尿病、血管障害及び腎臓疾患を治療又は予防するエストラジオールメタボライトの投与
GB0123961D0 (en) 2001-10-05 2001-11-28 Astrazeneca Ab Process and intermediates
KR20040053210A (ko) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
CA2465117C (en) 2001-11-06 2012-01-03 Brigham And Women's Hospital, Inc. Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
GB2388111A (en) 2002-05-01 2003-11-05 Bayer Ag Novel imidazotriazinone compounds
US6684626B1 (en) 2002-07-30 2004-02-03 General Electric Company Aircraft gas turbine engine with control vanes for counter rotating low pressure turbines
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
US20060100278A1 (en) 2002-08-20 2006-05-11 Cooper Garth J S Dosage forms and related therapies
EP1558237A4 (en) 2002-09-27 2007-01-17 Martek Biosciences Corp IMPROVED BLOOD SUGAR CONTROL F RPRU-DIABETES AND / OR DIABETES TYPE II USING DOCOSAHEXAENSURE
US7326421B2 (en) 2002-10-21 2008-02-05 Kensey Nash Corporation Device and methods for sequential, regional delivery of multiple cytotoxic agents and directed assembly of wound repair tissues
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
WO2005016864A1 (en) 2003-07-29 2005-02-24 The Arizona Disease Control Research Commission Conjugated nitro alkene anticancer agents based on isoprenoid metabolism
US20050136103A1 (en) 2003-09-17 2005-06-23 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US7935365B2 (en) 2003-10-22 2011-05-03 Enzymotec, Ltd. Glycerophospholipids for the improvement of cognitive functions
BRPI0416118A (pt) 2003-10-31 2007-01-02 Pfizer Prod Inc inibição da fosfodiesterase 9 como tratamento para estados relacionados com a obesidade
JP2007522118A (ja) 2004-01-30 2007-08-09 ペプリン バイオリピッズ ピーティーワイ エルティーディー 治療用分子および担体分子
CA2563533C (en) 2004-04-15 2013-10-01 Shmuel A. Ben-Sasson Compositions capable of facilitating penetration across a biological barrier
WO2005110396A2 (en) 2004-04-28 2005-11-24 Uab Research Foundation Nitrated lipids and methods of making and using thereof
CN101027318B (zh) 2004-07-19 2016-05-25 比奥孔有限公司 胰岛素-低聚物共轭物，制剂及其用途
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
EP1772149A1 (en) 2004-07-27 2007-04-11 Kowa Company. Ltd. Drug for prevention or treatment of diabetes
CA2588166A1 (en) 2004-11-19 2006-05-26 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
EP1817009A2 (en) * 2004-11-24 2007-08-15 Spi Pharma, Inc. Orally disintegrating compositions
AU2011202664B2 (en) 2004-12-08 2012-04-05 Cedars-Sinai Medical Center Methods for diagnosis and treatment of Crohn's disease
US20070032420A1 (en) 2005-02-09 2007-02-08 Entelos, Inc. Treating diabetes with glucagon-like peptide-1 secretagogues
EP1928237A4 (en) 2005-09-02 2011-03-09 Abbott Lab NEW HETEROCYCLES BASED ON IMIDAZO
GB0522569D0 (en) 2005-11-04 2005-12-14 Univ Bath Biocompatible drug delivery device
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US9274129B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
WO2008008767A2 (en) 2006-07-14 2008-01-17 Cedars-Sinai Medical Center Methods of using ppar-gamma agonists and caspase-dependent chemotherapeutic agents for the treatment of cancer
BRPI0714562A2 (pt) 2006-07-19 2013-04-02 Resolvyx Pharmaceuticals Inc composiÇÕes e mÉtodos para o tratamento de mucosites
WO2008029589A1 (en) 2006-09-08 2008-03-13 Tokuyama Corporation Method and equipment for producing group-iii nitride
AU2007332439A1 (en) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. Therapeutic agent for urinary tract disease
WO2008072779A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. キノキサリン誘導体
EP2120920A4 (en) 2007-02-20 2011-06-15 Martek Biosciences Corp OXYLIPINES OF LONG-CHAIN MULTIPLE-UNSATURATED FATTY ACIDS AND METHOD FOR THEIR PREPARATION AND USE
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
EP2679224A1 (en) 2007-08-01 2014-01-01 University of Pittsburgh of the Commonwealth System of Higher Education Nitro oleic acid modulation of type II diabetes
EP2207543A2 (en) 2007-09-14 2010-07-21 Resolvyx Pharmaceuticals, Inc. Omega-3 fatty acids, hydroxy polyunsaturated fatty acids, lipoxin compounds, or oxylipin compounds for treating autoimmune diseases or inhibiting immune function
US20110092594A1 (en) 2008-04-18 2011-04-21 Tianxin Yang Use of nitrated lipids for treatment of lipid disorders and obesity, and lipid- and obesity-related conditions
DK2280928T3 (en) 2008-05-01 2018-11-05 Complexa Inc Vinyl-substituted fatty acids
WO2009149496A1 (en) 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
CN102099024B (zh) 2008-06-19 2015-11-25 犹他大学研究基金会 硝化脂质在毒性医疗疗法的副作用的治疗上的用途
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
ES2622559T3 (es) 2008-07-29 2017-07-06 Nerviano Medical Sciences S.R.L. Combinación terapéutica que comprende un inhibidor de cdk y un agente antineoplásico
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
JP2012513774A (ja) 2008-12-31 2012-06-21 ニトロメガ コーポレーション ニトロ脂肪酸を含有する栄養補助物
US8937194B2 (en) 2008-12-31 2015-01-20 Nitromega Corp. Topical compositions containing nitro fatty acids
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
US20100286271A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Nitro-alkyl Compound Compositions
US20100286272A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkene Compositions In Dermatologic Applications
US20100286257A1 (en) 2009-05-08 2010-11-11 Perricone Nicholas V Methods Of Use Of Nitroalkane Compositions In Dermatologic Applications To Prevent or Treat Skin Aging
EP2456311A4 (en) 2009-07-24 2013-01-23 Concert Pharmaceuticals Inc SUBSTITUTED IMIDASOTRIAZINES
KR20120046754A (ko) 2009-07-29 2012-05-10 페노미넘 디스커버리스 인코포레이티드 히드록시 지방산 화합물 및 질병 치료 및 진단을 위한 그의 용도
CA2769624C (en) 2009-07-31 2018-09-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Electrophilic fatty acid derivatives as anti-inflammatory agents
WO2011028820A1 (en) 2009-09-02 2011-03-10 Concert Pharmaceuticals, Inc. Substituted derivatives of bicyclic [4.3.0] heteroaryl compounds
WO2011030351A2 (en) * 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
WO2011041639A2 (en) 2009-10-02 2011-04-07 Miller Raymond A Heteroatom containing substituted fatty acids
US20130005730A1 (en) 2009-11-09 2013-01-03 Piaoyang Sun Novel 1,3-oxazolidine compounds and their use as renin inhibitors
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
WO2011113507A2 (en) 2010-03-15 2011-09-22 Ulrich Dietz Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns
BR112012027915A2 (pt) 2010-05-13 2018-10-23 Nitromega Corp nitro-ácidos graxos - neuroproteção e/ou inibição do declínio cognitivo
EP2590643A4 (en) 2010-06-28 2014-01-01 Complexa Inc MEDICINAL PRODUCT MADE FROM SEVERAL INGREDIENTS FOR THE TREATMENT OF DIABETES
EP3181566A1 (en) 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
US8809345B2 (en) 2011-02-15 2014-08-19 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
EP2744491B1 (en) 2011-08-19 2020-07-29 The University of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
CN103930423B (zh) * 2011-10-07 2015-09-16 卫材Rd管理有限公司 吡唑并喹啉衍生物
MX381326B (es) 2011-10-10 2025-03-12 H Lundbeck As Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos
US9271952B2 (en) 2011-10-11 2016-03-01 Complexa, Inc. Compositions and methods for treating nephropathy
DE102012008730A1 (de) 2011-12-02 2013-06-06 Dr. Budz GmbH Orale Zusammensetzungen mit ungesättigten C18-Fettsäuren und ihre Verwendung
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
JP6038184B2 (ja) 2012-02-01 2016-12-07 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ リボヌクレオチドレダクターゼ阻害剤および使用方法
US10435367B2 (en) 2013-03-14 2019-10-08 City Of Hope Indirubin derivatives, and uses thereof
WO2013116753A1 (en) 2012-02-03 2013-08-08 University Of Pittsburgh-Of The Commonwelth System Of Higher Education Fatty acids as anti-inflammatory agents
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc IMIDAZOTRIAZINONVERBINDUNGEN
US10058688B2 (en) 2012-05-09 2018-08-28 Massachusetts Institute Of Technology Medicament, method, and drug delivery device for treatment of ovarian cancer
SI2890384T1 (sl) 2012-08-31 2022-02-28 Taris Biomedical Llc Sistemi za dostavo zdravila in postopki za zdravljenje raka sečnega mehurja, ki obsegajo oksaliplatin
US20140271844A1 (en) 2013-03-15 2014-09-18 Nitromega Corp. Compositions containing nitro fatty acids
CA2944480C (en) 2013-04-10 2021-05-18 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
WO2014183108A1 (en) 2013-05-10 2014-11-13 Nitromega Corp. Nutritional or dietary supplements containing fatty acids and nitrite
WO2014204872A2 (en) 2013-06-14 2014-12-24 Complexa, Inc. Composition and method for inhibition of pkng from mycobacterium tuberculosis
WO2015023557A1 (en) 2013-08-12 2015-02-19 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
WO2015073527A1 (en) 2013-11-12 2015-05-21 Complexa, Inc. Nitroalkene tocopherols and analogs thereof for use in the treatment and prevention of inflammation related conditions
WO2015185499A1 (en) 2014-06-06 2015-12-10 H. Lundbeck A/S Pde9 inhibitors with 1-benzyl-2,5,6,8-tetrahydro-3-oxo-2,7-naphthyridine-4-carbonitrile backbone
US20180092948A1 (en) 2015-04-02 2018-04-05 Aobiome Llc Production of nitro-fatty acids and nitro-hydrocarbons by ammonia oxidizing bacteria
CA2990521C (en) 2015-07-07 2023-10-10 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
CN113440506A (zh) 2015-10-02 2021-09-28 康普莱克夏公司 使用治疗有效量的活化脂肪酸预防、治疗和逆转疾病
WO2017141116A1 (en) 2016-02-19 2017-08-24 Phoenix Molecular Designs Carboxamide derivatives useful as rsk inhibitors
CN106389367B (zh) * 2016-11-16 2020-12-18 杭州朱养心药业有限公司 吡仑帕奈包衣片剂药物组合物
WO2018112078A1 (en) 2016-12-14 2018-06-21 Amgen Inc. Gastro-retentive modified release dosage forms for oprozomib and process to make thereof
HUE065158T2 (hu) 2017-05-26 2024-05-28 Cardurion Pharmaceuticals Inc PDE9 gátlószereinek elõállítására és alkalmazására szolgáló eljárások
BR112020024019A2 (pt) 2018-05-25 2021-02-23 Imara Inc. monoidrato e formas cristalinas de 6-[(3s,4s)-4-metil-1-(pirimidin-2-ilmetil)pirrolidin-3-il]-3-tetra-hidropiran-4-il-7h-imidazo[1,5-a]pirazin-8-ona
KR20250108770A (ko) 2018-08-31 2025-07-15 카듀리온 파마슈티칼스, 인크. 겸상 세포 질환의 치료를 위한 pde9 억제제
WO2020206336A1 (en) 2019-04-05 2020-10-08 Imara Inc. Pde9 inhibitors for treating sickle cell disease
CN114072151A (zh) 2019-05-07 2022-02-18 伊马拉公司 用于治疗地中海贫血的pde9抑制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018009424A1 (en) * 2016-07-06 2018-01-11 Imara, Inc. Pde9 inhibitors for treatment of peripheral diseases

Also Published As

Publication number Publication date
WO2020047311A1 (en) 2020-03-05
AU2025203611A1 (en) 2025-06-12
CN119679736A (zh) 2025-03-25
EP3843737A4 (en) 2022-06-01
EP3843737A1 (en) 2021-07-07
JP2025020208A (ja) 2025-02-12
US20210177845A1 (en) 2021-06-17
US12213975B2 (en) 2025-02-04
IL281032A (en) 2021-04-29
BR112021003686A2 (pt) 2021-05-18
KR20250108770A (ko) 2025-07-15
AU2019328299A1 (en) 2021-04-22
CN112996512B (zh) 2025-01-03
KR20210053948A (ko) 2021-05-12
JP2021535908A (ja) 2021-12-23
JP7579239B2 (ja) 2024-11-07
CA3110680A1 (en) 2020-03-05
US20250120974A1 (en) 2025-04-17
MA53501A (fr) 2021-07-07
CN112996512A (zh) 2021-06-18
JP7887940B2 (ja) 2026-07-10
KR102831968B1 (ko) 2025-07-08

Similar Documents

Publication Publication Date Title
US20250120974A1 (en) Pde9 inhibitors for treating sickle cell disease
US9532984B2 (en) Therapeutic combination for cancer treatment
US20220047589A1 (en) Pde9 inhibitors for treating thalassemia
CN103230394A (zh) 治疗肿瘤性疾病的化合物及其用途
US20220023302A1 (en) Pde9 inhibitors for treating sickle cell disease
WO2022036111A1 (en) Methods and compositions for treating sickle cell disease
WO2024073672A1 (en) Combination therapy with sparsentan and a sglt2 inhibitor for treating kidney diseases or disorders
IL322689A (en) Compositions and methods of using eflornithine
BR122025029113A2 (pt) Composições farmacêuticas orais compreendendo inibidores de pde9 e seus usos no tratamento de doença falciforme
BR112021003686B1 (pt) Composição farmacêutica na forma de comprimido oral compreendendo inibidores de pde9
EA052602B1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ 6-[(3S,4S)-4-МЕТИЛ-1-(ПИРИМИДИН-2-ИЛМЕТИЛ)ПИРРОЛИДИН-3-ИЛ]-3-ТЕТРАГИДРОПИРАН-4-ИЛ-7H-ИМИДАЗО[1,5-a]ПИРАЗИН-8-ОНА В ФОРМЕ ТАБЛЕТКИ
CN102552210B (zh) 一种恩替卡韦胶囊组合物及其制备方法
CN119606954B (zh) 一种替韦立马组合物及其制备方法和应用
US12011502B2 (en) Compositions and methods of administering baclofen
CN100584854C (zh) 圆锥绣球有效部位、其制备方法及其组合物与用途
II et al. PA, 19134, USA.
WO2018129463A1 (en) Co-administration of minocycline and colistin to reduce acute kidney injury
CN108785249A (zh) 含三苯双脒纳米超微粉的剂型
Tablets Full Prescribing Information
HK40085372B (en) Method for treating vaso occlusive crises associated with sickle cell disease

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CARDURION PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): IMARA INC.

FGA Letters patent sealed or granted (standard patent)